Vivjoa

(Oteseconazole - antifungal therapy 1)

PreclinicalSmall molecule

MMycovia Pharmaceuticals Inc.

Vivjoa is one of 50 small molecule programs targeting Cryptococcal Meningitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Cryptococcal MeningitisActive, not recruiting

HIVRecruiting

Cryptococcal MeningitisPhase 2/Phase 3

Active, not recruiting

HIVPreclinical

Recruiting

Competition

Competitive Landscape

57 competitors in HIV

#DrugCompanyPhaseTrials

Cabenuva

GSK

Approved

1 2

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Tivicay

3 4

Epivir

GGlaxo Dba Glaxosmithkline

Phase 3

10 5

Vemlidy

Gilead

Phase 3

1 6

Sunlenca

Gilead

Phase 3

1 7

Biktarvy

Gilead

Phase 3

1 8

Emtriva

Gilead

Phase 3

1 9

Priftin

Sanofi

Phase 2

1 10

Lamprene

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

PreclinicalRecruiting

HIV

NCT06666322

Clinical

Trials by Indication[1]

HIV1 trial

Platform Trial For Cryptococcal Meningitis

Recruiting·UUniversity of Minnesota·Preclinical·NCT06666322·2,000 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 26, 2022

VIVJOA

NDA NDA215888

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oteseconazole - antifungal therapy 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oteseconazole - antifungal therapy 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oteseconazole - antifungal therapy 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA215888). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Vivjoa. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Mycovia Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMycovia Pharmaceuticals Inc.

Patent Landscape[5]

Patent Cliff

Apr 22, 2031

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8754227Apr 22, 2031

8236962Apr 22, 2031

11247981May 9, 2033

9840492Mar 17, 2036

10414751Mar 17, 2036

Vivjoa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

HIV1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News